{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T14:29:48Z","timestamp":1780669788617,"version":"3.54.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.jaad.2009.10.033","type":"journal-article","created":{"date-parts":[[2010,8,3]],"date-time":"2010-08-03T05:59:53Z","timestamp":1280815193000},"page":"602-606","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Use of warfarin therapy at a target international normalized ratio of 3.0 for cutaneous polyarteritis nodosa"],"prefix":"10.1016","volume":"63","author":[{"given":"Tamihiro","family":"Kawakami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinao","family":"Soma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2009.10.033_bib1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.sder.2007.02.003","article-title":"Cutaneous polyarteritis nodosa","volume":"26","author":"D\u00edaz-P\u00e9rez","year":"2007","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.jaad.2009.10.033_bib2","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/art.23081","article-title":"High titer of anti-phosphatidylserine-prothrombin complex antibodies in patients with cutaneous polyarteritis nodosa","volume":"57","author":"Kawakami","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2009.10.033_bib3","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMra002974","article-title":"The antiphospholipid syndrome","volume":"346","author":"Levine","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2009.10.033_bib4","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1046\/j.1538-7836.2003.00125.x","article-title":"Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease","volume":"1","author":"Arnout","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jaad.2009.10.033_bib5","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.thromres.2004.06.010","article-title":"How much warfarin is enough in APS related thrombosis?","volume":"114","author":"Erkan","year":"2004","journal-title":"Thromb Res"},{"key":"10.1016\/j.jaad.2009.10.033_bib6","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/art.23528","article-title":"High titer of serum antiphospholipid antibody levels in adult Henoch-Sch\u00f6nlein purpura and cutaneous leukocytoclastic angiitis","volume":"59","author":"Kawakami","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2009.10.033_bib7","doi-asserted-by":"crossref","first-page":"911","DOI":"10.7326\/0003-4819-149-12-200812160-00018","article-title":"Remission of hepatitis B virus-related cryoglobulinemic vasculitis with entecavir","volume":"149","author":"Kawakami","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2009.10.033_bib8","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJM199504133321504","article-title":"The management of thrombosis in the antiphospholipid-antibody syndrome","volume":"332","author":"Khamashta","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2009.10.033_bib9","doi-asserted-by":"crossref","first-page":"303","DOI":"10.7326\/0003-4819-117-4-303","article-title":"Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients","volume":"117","author":"Rosove","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2009.10.033_bib10","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/ard.52.9.689","article-title":"Patients with antiphospholipid antibodies and venous thrombosis should receive long-term anticoagulant treatment","volume":"52","author":"Derksen","year":"1993","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2009.10.033_bib11","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0002-9343(98)00060-6","article-title":"Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group","volume":"104","author":"Schulman","year":"1998","journal-title":"Am J Med"},{"key":"10.1016\/j.jaad.2009.10.033_bib12","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1182\/blood.V86.10.3685.bloodjournal86103685","article-title":"Antiphospholipid antibodies and venous thromboembolism","volume":"86","author":"Ginsberg","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2009.10.033_bib13","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1055\/s-0038-1650380","article-title":"Antiphospholipid antibodies, recurrent thromboembolism, and intensity of warfarin anticoagulation","volume":"75","author":"Prandoni","year":"1996","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jaad.2009.10.033_bib14","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1055\/s-0038-1655939","article-title":"Anticardiolipin antibodies and recurrent thromboembolism","volume":"77","author":"Rance","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jaad.2009.10.033_bib15","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1056\/NEJMoa035241","article-title":"A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome","volume":"349","author":"Crowther","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2009.10.033_bib16","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1001\/jama.295.9.1050","article-title":"Management of antiphospholipid antibody syndrome: a systematic review","volume":"295","author":"Lim","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2009.10.033_bib17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.rdc.2005.09.004","article-title":"New treatments for antiphospholipid syndrome","volume":"32","author":"Erkan","year":"2006","journal-title":"Rheum Dis Clin North Am"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962209013644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962209013644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:17:26Z","timestamp":1759270646000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962209013644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0190962209013644"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2009.10.033","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.5524958.5491060","asserted-by":"object"}]},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of warfarin therapy at a target international normalized ratio of 3.0 for cutaneous polyarteritis nodosa","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2009.10.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}